GSK and Ionis won FDA approval for bepirovirsen, now branded Hibsago, a chronic hepatitis B therapy designed to target the genetic instructions the virus uses to produce its proteins and to pursue a potential functional cure. The approval adds to a small but growing category of nucleic-acid approaches aimed at achieving sustained viral control without lifelong suppression. Regulators’ decision positions Hibsago alongside other functional-cure strategies that combine immune restoration with viral targeting. GSK is also positioning the asset to be a commercial scale driver as it targets significant growth milestones. For biotech development teams, the Hibsago label clarifies that antisense biology can translate into an FDA path for chronic HBV—potentially sharpening competitive focus on similar sequence-targeting designs, patient selection, and long-term durability endpoints.